These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 32036861

  • 1. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.
    O'Meara E, McDonald M, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Grzeslo A, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk LM, Moe GW, Swiggum E, Toma M, Virani SA, Zieroth S, De S, Matteau S, Parent MC, Asgar AW, Cohen G, Fine N, Davis M, Verma S, Cherney D, Abrams H, Al-Hesayen A, Cohen-Solal A, D'Astous M, Delgado DH, Desplantie O, Estrella-Holder E, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Lee D, Masoudi FA, McKelvie RS, Rajda M, Ross HJ, Sussex B.
    Can J Cardiol; 2020 Feb; 36(2):159-169. PubMed ID: 32036861
    [Abstract] [Full Text] [Related]

  • 2. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    Packer M, Kitzman DW.
    JACC Heart Fail; 2018 Aug 19; 6(8):633-639. PubMed ID: 29525327
    [Abstract] [Full Text] [Related]

  • 6. The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review.
    Ezhumalai B, Modi R, Panchanatham M, Kaliyamoorthy D.
    Indian Heart J; 2024 Aug 19; 76(4):229-239. PubMed ID: 39009078
    [Abstract] [Full Text] [Related]

  • 7. Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).
    S H, Oomman A, Jadhav UM, Raghuraman B, Mohanan PP, Tiwaskar M, Wander GS, Chopra VK.
    J Assoc Physicians India; 2022 Aug 19; 70(8):11-12. PubMed ID: 36082729
    [Abstract] [Full Text] [Related]

  • 8. Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Dixit NM, Truong KP, Vaduganathan M, Ziaeian B, Fonarow GC.
    JACC Heart Fail; 2024 Jul 19; 12(7):1226-1237. PubMed ID: 38703159
    [Abstract] [Full Text] [Related]

  • 9. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
    Mareev YV, Mareev VY.
    Kardiologiia; 2021 Jul 01; 61(6):4-10. PubMed ID: 34311683
    [Abstract] [Full Text] [Related]

  • 10. Indian Consensus on the Role and Position of Angiotensin Receptor-neprilysin Inhibitors in the Management of Heart Failure.
    Chopra HK, Ponde C, Wander GS, Nair T, Ray S, Khullar D, Nanda NC, Narula J, Kasliwal RR, Rana DS, Kirpalani A, Sawhney JS, Chandra P, Mehta Y, Kumar V, Tiwari S, Pancholia AK, Kher V, Bansal S, Mittal S, Kerkar P, Sahoo PK, Hotchandani R, Prakash S, Chauhan N, Rastogi V, Abdullakutty J, Shanmugasundaram S, Tiwaskar M, Sinha A, Gupta V, Mishra SS, Routray SN, Omar AK, Swami OC, Jaswal A, Alam S, Passey R, Rajput R, Paul J, Kapoor A, Dorairaj P, Chandra S, Malhotra P, Singh VP, Bansal M, Jain S, Shah P, Bhargava M, Vijayalakshmi IB, Varghaese K, Jain D, Goel A, Mahmood K, Gaur N, Tandon R, Moorthy A, George S, Katyal VK, Mantri RR, Mehrotra R, Bhalla D, Mittal V, Rao S, Jagia M, Singh H, Awasthi S, Sattur A, Mishra R, Pandey A, Chawla R, Jaggi S, Sehgal B, Sehgal A, Goel N, Gupta R, Kubba S, Chhabra A, Bagga S, Shastry RN.
    J Assoc Physicians India; 2024 Sep 01; 72(9):75-82. PubMed ID: 39291524
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ, Butler J, Kosiborod MN.
    Am J Med; 2024 Feb 01; 137(2S):S25-S34. PubMed ID: 38184323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
    Eur J Heart Fail; 2019 Oct 01; 21(10):1270-1278. PubMed ID: 31584231
    [Abstract] [Full Text] [Related]

  • 17. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA, Pinner NA, Lisenby KM, Osmonson A.
    Pharmacotherapy; 2021 Jun 01; 41(6):526-536. PubMed ID: 33866578
    [Abstract] [Full Text] [Related]

  • 18. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J, Flammer AJ, Palazzuoli A, Barragan PM, Thum T, Marcos MC, Miró Ò, Rossignol P, Metra M, Lassus J, Orso F, Jankowska EA, Chioncel O, Milicic D, Hill L, Seferovic P, Rosano G, Coats A, Damman K.
    Eur J Heart Fail; 2022 Apr 01; 24(4):603-619. PubMed ID: 35239201
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.